HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

78.400

+1.0501.36%

Volume:27.80M

Turnover:2.16B

Market Cap:129.60B

PE:-1.23K

High:80.800

Open:78.800

Low:75.600

Close:77.350

Loading ...

Overview Company News Filings

BUZZ-HUTCHMED hits 2-month high on drug application for kidney cancer treatment

Innovent's Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) Receives Second Nmpa Breakthrough Therapy Designation for Immuno-Resistant Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS

BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab

Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%

MT Newswires Live

Innovent Biologics Announces Promising Phase 1/2 Results for IBI354 in Advanced Solid Tumors at 2025 ASCO Meeting

Innovent Biologics Presents Promising Phase 1 Results for IBI363 in Advanced Colorectal Cancer at 2025 ASCO Meeting

2025 Asco Oral Presentation: Innovent Biologics Announces Updated Date of Ibi363 (First-in-Class Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) From Phase 1 Clinical Studies in Advanced Colorectal Cancer

THOMSON REUTERS

Innovent Biologics Announces Groundbreaking Phase 2 Trial of IBI363 for Treatment-Resistant Melanoma at ASCO 2025

Asco 2025 Oral Presentation: Innovent Biologics Announces Updated Data of Ibi363 (First-in-Class Pd-1/Il-2Α -Bias Bispecific Antibody Fusion Protein) From Phase 1 and 2 Clinical Studies on Immunotherapy-Treated Advanced Malignant Melanoma

THOMSON REUTERS

Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response

Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies

THOMSON REUTERS

Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment

HK Movers | HK's Pharma Shares Soar. Hengrui Pharma Surges 29%; Asymchem up 7%; CSPC Pharma up 4%

Tiger Newspress

Innovent Biologics Unveils 2024 ESG Report, Achieves Rare AAA MSCI Rating

Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China

Bolt Biotherapeutics Reports 77% Drop in Q1 Collaboration Revenue, Narrows Operational Loss to $12.1 Million

Innovent Biologics Launches Phase 2 Clinical Study of Efdamrofusp Alfa for Diabetic Macular Edema Treatment

Bispecific VS. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (Ibi302), a First-in-Class Anti-Vegf and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

THOMSON REUTERS

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (Ibi302), First-in-Class Anti-Vegf/Complement Bispecific Fusion Protein at Arvo 2025

THOMSON REUTERS

Innovent Biologics Logs 40% Boost in Q1 Product Revenue

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/01801/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01801","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01801\",,,,,undefined,":{"symbol":"01801","market":"HK","secType":"STK","nameCN":"INNOVENT BIO","latestPrice":78.4,"timestamp":1751270891013,"preClose":77.35,"halted":0,"volume":27799285,"delay":0,"floatShares":1653000000,"shares":1653000000,"eps":-0.06372745744355238,"marketStatus":"Not Yet Opened","change":1.05,"latestTime":"06-30 16:08:11","open":78.8,"high":80.8,"low":75.6,"amount":2162431011,"amplitude":0.067227,"askPrice":78.4,"askSize":83500,"bidPrice":78.35,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.06575942363383797,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1751419800000},"marketStatusCode":0,"adr":0,"listingDate":1540915200000,"exchange":"SEHK","adjPreClose":77.35,"openAndCloseTimeList":[[1751247000000,1751256000000],[1751259600000,1751270400000]],"volumeRatio":1.001588473701527,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"INB.HK","impliedVol":0.6361,"impliedVolPercentile":0.7724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01801\",,,,,undefined,":{"symbol":"01801","floatShares":1653000000,"roa":"-0.82%","roe":"-0.74%","lyrEps":-0.063732,"volumeRatio":1.001588473701527,"shares":1653000000,"dividePrice":0,"high":80.8,"amplitude":0.067227,"preClose":77.35,"low":75.6,"week52Low":28.65,"pbRate":"9.01","psRate":"12.55","week52High":83.8,"institutionHeld":0,"latestPrice":78.4,"committee":-0.908571,"eps":-0.0637320905601733,"divideRate":0,"volume":27799285,"delay":0,"ttmEps":-0.06576420447856084,"open":78.8,"prevYearClose":36.6,"prevWeekClose":77.35,"prevMonthClose":78.4,"prevQuarterClose":78.4,"fiveDayClose":78.9,"twentyDayClose":63.1,"sixtyDayClose":46.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01801\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541041883","title":"BUZZ-HUTCHMED hits 2-month high on drug application for kidney cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2541041883","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541041883?lang=en_us&edition=fundamental","pubTime":"2025-06-05 15:35","pubTimestamp":1749108945,"startTime":"0","endTime":"0","summary":"BUZZ-HUTCHMED hits 2-month high on drug application for kidney cancer treatment ** Shares of biopharmaceutical group HUTCHMED  Ltd 0013.HK jump 9.7% to HK$26, their highest since April 2** Stock on course for third consecutive session of gains** HUTCHMED and nnovent Biologics 1801.HK say in a joint statement that China National Medical Products Administration  has accepted for review the New Drug Application for the combination of fruquintinib and sintilimab for treatment of renal cell carcinoma in kidney cancer** Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly LLY.N** Sintilimab is co-developed and co-commercialized by nnovent and Eli Lilly** Hong Kong's healthcare index .HSCIH falls 1.6%, Hang Seng Biotech Index .HSHKBIO drops 1.8%** YTD, HUTCHMEd stock up 5.8%   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nL2N3S806Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2361045086.USD","LU2461242641.AUD","LU1868836914.USD","LU2112291526.USD","LU0354030438.USD","LU0266013472.USD","LU1551013425.SGD","LU1983299246.USD","LU2462157665.USD","LU2361044949.HKD","SGXZ81514606.USD","LU0820561818.USD","BK4533","LU0079474960.USD","LU2491049909.HKD","LU0320765992.SGD","LU0466842654.USD","LU0256863811.USD","00013","LU1868836591.USD","LU0689472784.USD","LU0943347566.SGD","LU1969619763.USD","LU2491050154.USD","SGXZ57979304.SGD","BK4534","LU1917777945.USD","LU2471134952.CNY","BK1588","LU2357305700.SGD","SG9999014906.USD","LU2264538146.SGD","LU2328871848.SGD","BK4581","LU2491050071.SGD","LU0203202063.USD","LU0882574139.USD","LU2471134879.HKD","LU1127390331.HKD","LU1267930730.SGD","LU1868837136.USD","LU0058720904.USD","LU0323591593.USD","LU0198837287.USD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0823416689.USD","SGXZ31699556.SGD","01801"],"gpt_icon":1},{"id":"2541090441","title":"Innovent's Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) Receives Second Nmpa Breakthrough Therapy Designation for  Immuno-Resistant Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2541090441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541090441?lang=en_us&edition=fundamental","pubTime":"2025-06-05 08:23","pubTimestamp":1749082994,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nTUAGHKW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2488822045.USD","BK1583","BK1161","LU2328871848.SGD","BK1589","LU1969619763.USD","01801"],"gpt_icon":0},{"id":"2541097438","title":"BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With Sintilimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2541097438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541097438?lang=en_us&edition=fundamental","pubTime":"2025-06-05 07:47","pubTimestamp":1749080867,"startTime":"0","endTime":"0","summary":"BRIEF-HUTCHMED (China) Says NDA Acceptance In China For Fruquintinib Combination With SintilimabJune 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK:NDA ACCEPTANCE IN CHINA FOR FRUQUINTINIB COMBINATION WIT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nFWN3S70VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1588","BK1583","BK1161","LU2488822045.USD","BK1191","01801","LU2328871848.SGD","00013","LU1969619763.USD","BK1589"],"gpt_icon":0},{"id":"2540799031","title":"Innovent's Phase 1 Trial for Lung Cancer Drug Shows Manageable Safety, Long-Term Survival Benefits; Shares Surge 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540799031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540799031?lang=en_us&edition=fundamental","pubTime":"2025-06-04 15:10","pubTimestamp":1749021006,"startTime":"0","endTime":"0","summary":"Innovent Biologics'  IBI363 medication for immunotherapy-resistant non-small cell lung cancer and wild-type lung adenocarcinoma showed a manageable safety profile, efficacy, and long-term survival benefits during its phase 1 study.The drug company presented the findings during the 2025 American Society of Clinical Oncology Conference, according to a Wednesday news release.IBI363 also showed breakthrough therapeutic potential from tumor response to long-term survival benefits for patients with immuno-resistant squamous non-small cell lung cancer, and wild-type lung adenocarcinoma, especially with those who smoked.Shares surged 14% during Wednesday's afternoon trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","LU2488822045.USD","BK1161","LU1969619763.USD","01801","LU2328871848.SGD","BK1589"],"gpt_icon":0},{"id":"2540080714","title":"Innovent Biologics Announces Promising Phase 1/2 Results for IBI354 in Advanced Solid Tumors at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540080714","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540080714?lang=en_us&edition=fundamental","pubTime":"2025-06-03 09:00","pubTimestamp":1748912422,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., a leading biopharmaceutical company, has announced updated clinical data for IBI354, a novel anti-HER2 antibody-drug conjugate , during the 2025 American Society of Clinical Oncology  Annual Meeting. The data, derived from a Phase 1/2 clinical study, highlights the promising anti-tumor efficacy and favorable safety profile of IBI354 across various advanced solid tumors, including ovarian and breast cancer. This study included 368 participants and demonstrated no dose-limiting toxicities at doses up to 18mg/kg, with the most common treatment-related adverse events being anemia, nausea, and a decrease in white blood cell count. The incidence of interstitial lung disease was low at 1.9% and limited to grades 1-2. These findings support Innovent's ongoing development of next-generation ADC therapies and further clinical studies are planned, including a Phase 3 study in platinum-resistant ovarian cancer.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL2BQ6zS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","BK1161","BK1589","BK1583","BK1147","LU1969619763.USD","LU2488822045.USD","LU2328871848.SGD","01911"],"gpt_icon":0},{"id":"2540753909","title":"Innovent Biologics Presents Promising Phase 1 Results for IBI363 in Advanced Colorectal Cancer at 2025 ASCO Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2540753909","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540753909?lang=en_us&edition=fundamental","pubTime":"2025-06-02 08:00","pubTimestamp":1748822424,"startTime":"0","endTime":"0","summary":"Innovent Biologics, Inc. has announced promising results from its Phase 1 studies evaluating IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, in patients with advanced colorectal cancer. The data, presented at the 2025 American Society of Clinical Oncology  Annual Meeting, indicate that IBI363, both as monotherapy and in combination with bevacizumab, shows encouraging responses and overall survival benefits. These findings are particularly noteworthy given colorectal cancer's reputation as an immunologically 'cold' tumor. The studies, conducted in China, the United States, and Australia, underscore IBI363's potential to convert 'cold tumors' into 'hot tumors,' suggesting significant promise for broader clinical development and potential new treatment avenues in immunotherapy-resistant and cold tumor indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL1f2vDz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU2328871848.SGD","01801","LU2488822045.USD","LU1969619763.USD","BK1161","01911","BK1583","BK1147"],"gpt_icon":0},{"id":"2540753935","title":"2025 Asco Oral Presentation: Innovent Biologics Announces Updated Date of Ibi363 (First-in-Class Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) From Phase 1 Clinical Studies in Advanced Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2540753935","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540753935?lang=en_us&edition=fundamental","pubTime":"2025-06-02 08:00","pubTimestamp":1748822402,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nTUA1KZZ4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","LU2328871848.SGD","01801","LU2488822045.USD","LU1969619763.USD","BK1161","BK1583"],"gpt_icon":0},{"id":"2540780236","title":"Innovent Biologics Announces Groundbreaking Phase 2 Trial of IBI363 for Treatment-Resistant Melanoma at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2540780236","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540780236?lang=en_us&edition=fundamental","pubTime":"2025-06-01 09:39","pubTimestamp":1748741995,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced updated data from its Phase 1 and Phase 2 clinical studies on IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at the 2025 American Society of Clinical Oncology  Annual Meeting. This study focuses on patients with advanced malignant melanoma, particularly the acral and mucosal subtypes, which are typically resistant to treatment. The research has shown promising results in these hard-to-treat \"cold\" tumors. Innovent Biologics is also conducting a pivotal Phase 2 registrational trial comparing IBI363 monotherapy to pembrolizumab in patients with unresectable, locally advanced, or metastatic mucosal and acral melanoma. The trial aims to enroll 180 patients and will evaluate progression-free survival as the primary endpoint. IBI363 was generally well tolerated, with manageable safety profiles, and no new safety risks were identified.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL8gJRqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","BK1583","LU2328871848.SGD","LU1969619763.USD","01911","LU2488822045.USD","BK1161","01801","BK1589"],"gpt_icon":0},{"id":"2540474780","title":"Asco 2025 Oral Presentation: Innovent Biologics Announces Updated Data of Ibi363 (First-in-Class Pd-1/Il-2Α -Bias Bispecific Antibody Fusion Protein) From Phase 1 and 2 Clinical Studies on Immunotherapy-Treated Advanced Malignant Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2540474780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540474780?lang=en_us&edition=fundamental","pubTime":"2025-06-01 09:39","pubTimestamp":1748741981,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nTUA3V3C3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1969619763.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","BK1589","01801","BK1583"],"gpt_icon":0},{"id":"2539868342","title":"Innovent Biologics Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Prior Inadequate Anti-IL-17 Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2539868342","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539868342?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482418,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. Announces Phase 3 Clinical Study of Picankibart for Psoriasis Innovent Biologics, Inc. has announced the initiation of a Phase 3 clinical study to evaluate picankibart, an anti-IL-23p19 antibody, in treating psoriasis patients who have had an inadequate response to anti-IL-17 antibodies. The study recently completed the first participant dosing and is the first of its kind to explore biologics switching in this patient population. The trial will compare the efficacy of picankibart against IL-17 inhibitors. Previous Phase 2 data indicated that picankibart achieved significant skin lesion clearance in 64.6% of patients after 16 weeks. The study aims to provide clinical evidence supporting picankibart's use as an alternative treatment option for challenging cases of psoriasis. Innovent's new drug application for picankibart for moderate-to-severe plaque psoriasis is currently under review by the NMPA.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5yWrZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2328871848.SGD","LU1969619763.USD","BK1583","BK1147","BK1589","01911","BK1161","01801"],"gpt_icon":0},{"id":"2539891286","title":"Innovent Announces a Phase 3 Study of Picankibart (Anti-Il-23P19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients With Prior Inadequate Response to Anti-Il-17 Antibodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2539891286","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539891286?lang=en_us&edition=fundamental","pubTime":"2025-05-29 09:33","pubTimestamp":1748482401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nTUA4VKCRX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1589","BK1583","LU2328871848.SGD","LU2488822045.USD","LU1969619763.USD","BK1161","01801"],"gpt_icon":0},{"id":"2538808141","title":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2538808141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538808141?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:00","pubTimestamp":1748217619,"startTime":"0","endTime":"0","summary":"Innovent Biologics' Groundbreaking Phase 3 Study of Mazdutide in Chinese Adults Published in NEJM, Marks Milestone in Obesity Treatment. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire  on May 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL3LGflG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2488822045.USD","BK1161","LU2328871848.SGD","01911","BK1147","BK1589","01801","BK1583"],"gpt_icon":0},{"id":"1133424631","title":"HK Movers | HK's Pharma Shares Soar. Hengrui Pharma Surges 29%; Asymchem up 7%; CSPC Pharma up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133424631","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133424631?lang=en_us&edition=fundamental","pubTime":"2025-05-23 10:09","pubTimestamp":1747966164,"startTime":"0","endTime":"0","summary":"Hong Kong’s pharma stocks rose on Friday.Hengrui Pharma surged 29%; Asymchem rose 7%; CSPC Pharma rose 4%; Hutchmed, Innovent Bio, Laekna rose 3%; CanSinoBIO rose 2%.Hengrui, which is based in eastern China’s Jiangsu province, began operations in 1970 as state-owned Lianyungang Pharmaceutical Factory. It listed in Shanghai in 2000.Over the years, it has shifted focus to developing novel drugs from making generic medicines. It has spent 44 billion yuan  on R&D since 2000, according to its website","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"97c4ce10e0d7371cbbe9d36dff321fe2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","00013","01093","01276","06821","01801","02105"],"gpt_icon":1},{"id":"2536451705","title":"Innovent Biologics Unveils 2024 ESG Report, Achieves Rare AAA MSCI Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2536451705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536451705?lang=en_us&edition=fundamental","pubTime":"2025-05-19 08:00","pubTimestamp":1747612826,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., a leading biopharmaceutical company, has released its 2024 Environmental, Social and Governance  Report, highlighting its commitment to sustainable development. Key areas of focus include governance, health, quality, people, and ecology. Innovent has received an MSCI ESG rating of AAA, making it the only biotech in China and one of three globally to achieve this distinction. The company emphasizes its dedication to bridging healthcare gaps through innovative therapies and enhancing drug accessibility and affordability. Innovent's ESG efforts also include supplier compliance and community support initiatives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content us","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL92BcfJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","01801"],"gpt_icon":0},{"id":"2535802719","title":"Innovent Biologics Initiates Phase 3 Study of Mazdutide for Treating Obesity and MAFLD in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2535802719","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535802719?lang=en_us&edition=fundamental","pubTime":"2025-05-16 08:00","pubTimestamp":1747353620,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the commencement of the first participant dosing in their GLORY-3 Phase 3 clinical study in China. This study focuses on evaluating the efficacy and safety of mazdutide, a dual glucagon  and glucagon-like peptide 1 receptor  receptor agonist, compared to semaglutide in adults with overweight or obesity accompanied by metabolic dysfunction-associated fatty liver disease . The trial aims to enroll approximately 470 participants, assessing primary endpoints such as changes in liver fat content and body weight over 48 weeks. Innovent's Senior Vice President of Clinical Development, Dr. Lei Qian, expressed confidence in mazdutide's potential to provide comprehensive metabolic benefits and a better treatment option for Chinese patients struggling with obesity-related MAFLD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250516:nNDL3yw2wp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","BK1583","BK1161","01801","BK1589","LU2488822045.USD","LU1969619763.USD","BK1147","01911"],"gpt_icon":0},{"id":"2535789235","title":"Bolt Biotherapeutics Reports 77% Drop in Q1 Collaboration Revenue, Narrows Operational Loss to $12.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535789235","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535789235?lang=en_us&edition=fundamental","pubTime":"2025-05-13 04:05","pubTimestamp":1747080340,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bolt Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on May 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250512:nNDL7G4n2p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","NDAQ","BOLT"],"gpt_icon":0},{"id":"2533461763","title":"Innovent Biologics Launches Phase 2 Clinical Study of Efdamrofusp Alfa for Diabetic Macular Edema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2533461763","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533461763?lang=en_us&edition=fundamental","pubTime":"2025-05-07 08:24","pubTimestamp":1746577474,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the commencement of the Phase 2 clinical study for efdamrofusp alfa , a pioneering anti-VEGF and anti-complement bispecific fusion protein, aimed at treating diabetic macular edema . The study, which marks the first global comparison of two dual-target agents, includes 150 participants divided into three groups to evaluate the efficacy and safety of the drug. Efdamrofusp alfa, developed by Innovent, has shown promising results in earlier trials, offering the potential for improved visual acuity and extended dosing intervals for DME patients. This trial could pave the way for a Phase 3 clinical study and provide a new treatment option for millions affected by DME, particularly in China where the disease is a leading cause of vision impairment among diabetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL1nphf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","LU2488822045.USD","BK1589","01801","BK1583","BK1147","LU2328871848.SGD","LU1969619763.USD","BK1161"],"gpt_icon":0},{"id":"2533159692","title":"Bispecific VS. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (Ibi302), a First-in-Class Anti-Vegf and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2533159692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533159692?lang=en_us&edition=fundamental","pubTime":"2025-05-07 08:00","pubTimestamp":1746576003,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nTUA3V1JXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1969619763.USD","BK1583","BK1161","BK1589","LU2328871848.SGD","01801","LU2488822045.USD"],"gpt_icon":0},{"id":"2533938305","title":"Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (Ibi302), First-in-Class Anti-Vegf/Complement Bispecific Fusion Protein at Arvo 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2533938305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533938305?lang=en_us&edition=fundamental","pubTime":"2025-05-06 08:00","pubTimestamp":1746489603,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nTUA2SKCJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1161","LU2328871848.SGD","LU1969619763.USD","01801","BK1589","LU2488822045.USD"],"gpt_icon":0},{"id":"2532481316","title":"Innovent Biologics Logs 40% Boost in Q1 Product Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481316","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532481316?lang=en_us&edition=fundamental","pubTime":"2025-05-02 17:27","pubTimestamp":1746178069,"startTime":"0","endTime":"0","summary":"Innovent Biologics  recorded a total product revenue of over 2.4 billion yuan in the first quarter, up 40% from a year prior, a Thursday Hong Kong bourse filing said.The drugmaker launched four new products in the quarter, comprising Dovbleron, Limertinib, and Jaypirca in the oncology niche, and SYCUME in the field of general biomedicine.To date, the company has 15 approved products, three new drug applications under regulatory review, four assets in phase III or pivotal clinical trials, and 15 more molecules in early clinical stage.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01801"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":85,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01801\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"01801","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"Post Market","dateTimestamp":1742918400000,"actualEps":null},{"date":"2024-08-28","symbol":"01801","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724808600000,"name":null,"time":"","dateTimestamp":1724774400000,"actualEps":null},{"date":"2024-03-20","symbol":"01801","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1710898200000,"name":null,"time":"","dateTimestamp":1710864000000,"actualEps":null},{"date":"2023-08-23","symbol":"01801","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692754200000,"name":null,"time":"","dateTimestamp":1692720000000,"actualEps":null},{"date":"2023-03-28","symbol":"01801","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1679967000000,"name":null,"time":"","dateTimestamp":1679932800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01801\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01801\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.5385,"hold":0.0385,"sell":0.0385,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":26,"updateTime":1751299200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01801\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01801","date":"2025-06-30","current":-1248.706528,"percent":0.009756,"low":-1314.719354,"twenty":-60.856179,"median":-43.894007,"eighty":-19.437399,"high":-7.531991,"avg":-89.473208,"sd":208.240962,"marketCap":129484340596},"quantilePoints":[{"date":"2020-07-03","current":-42.15165,"twenty":-31.212367,"median":-21.5439,"eighty":-5.426457,"marketCap":79513042032},{"date":"2020-07-10","current":-41.718218,"twenty":-33.055097,"median":-23.009394,"eighty":-5.428958,"marketCap":79445885746},{"date":"2020-07-17","current":-36.617176,"twenty":-33.853843,"median":-23.56045,"eighty":-5.435413,"marketCap":69842536920},{"date":"2020-07-24","current":-35.392158,"twenty":-34.117248,"median":-23.759204,"eighty":-5.43938,"marketCap":67241749424},{"date":"2020-07-31","current":-34.790809,"twenty":-34.526864,"median":-24.13478,"eighty":-5.448361,"marketCap":66487246107},{"date":"2020-08-07","current":-36.619021,"twenty":-34.926791,"median":-24.303633,"eighty":-5.465712,"marketCap":70056561424},{"date":"2020-08-14","current":-36.782836,"twenty":-35.235669,"median":-24.961961,"eighty":-5.472343,"marketCap":70546467448},{"date":"2020-08-21","current":-40.576246,"twenty":-35.792876,"median":-25.584933,"eighty":-5.486343,"marketCap":78175004107},{"date":"2020-08-28","current":-43.795492,"twenty":-36.439174,"median":-26.421678,"eighty":-5.520251,"marketCap":79784695329},{"date":"2020-09-04","current":-39.665739,"twenty":-36.777743,"median":-27.271989,"eighty":-5.526185,"marketCap":72506091544},{"date":"2020-09-11","current":-42.988967,"twenty":-37.537428,"median":-27.599103,"eighty":-5.541887,"marketCap":78664910131},{"date":"2020-09-18","current":-47.462616,"twenty":-38.638915,"median":-28.066584,"eighty":-5.578764,"marketCap":87693178287},{"date":"2020-09-25","current":-44.177192,"twenty":-39.337069,"median":-29.168327,"eighty":-5.58909,"marketCap":80974467101},{"date":"2020-09-30","current":-43.635669,"twenty":-39.577106,"median":-29.30153,"eighty":-5.589358,"marketCap":80363386427},{"date":"2020-10-09","current":-45.526878,"twenty":-40.068119,"median":-30.400474,"eighty":-5.594485,"marketCap":85053584067},{"date":"2020-10-16","current":-50.643672,"twenty":-40.933846,"median":-30.680202,"eighty":-5.627514,"marketCap":94573985247},{"date":"2020-10-23","current":-47.907898,"twenty":-41.325791,"median":-32.326031,"eighty":-5.801767,"marketCap":89603775808},{"date":"2020-10-30","current":-42.811074,"twenty":-41.735504,"median":-32.968835,"eighty":-5.84909,"marketCap":80083374628},{"date":"2020-11-06","current":-42.967789,"twenty":-42.743927,"median":-33.29142,"eighty":-5.864706,"marketCap":81316323725},{"date":"2020-11-13","current":-40.934902,"twenty":-42.378258,"median":-33.900554,"eighty":-5.91801,"marketCap":77534169133},{"date":"2020-11-20","current":-41.561739,"twenty":-42.114631,"median":-34.056118,"eighty":-5.952614,"marketCap":79215126730},{"date":"2020-11-27","current":-38.270387,"twenty":-41.89284,"median":-34.145822,"eighty":-5.961576,"marketCap":72771455944},{"date":"2020-12-04","current":-42.094411,"twenty":-41.89284,"median":-34.507897,"eighty":-5.975351,"marketCap":80618802227},{"date":"2020-12-11","current":-41.498839,"twenty":-41.89284,"median":-34.562136,"eighty":-6.024626,"marketCap":79287996630},{"date":"2020-12-18","current":-49.483759,"twenty":-42.135729,"median":-34.875798,"eighty":-6.083138,"marketCap":94697324597},{"date":"2020-12-24","current":-53.344979,"twenty":-42.79967,"median":-35.04397,"eighty":-6.115628,"marketCap":102191861381},{"date":"2020-12-31","current":-60.05736,"twenty":-43.169204,"median":-35.327908,"eighty":-6.141418,"marketCap":115097770553},{"date":"2021-01-08","current":-59.811501,"twenty":-59.909844,"median":-58.854704,"eighty":-57.04374,"marketCap":115658880952},{"date":"2021-01-15","current":-65.889833,"twenty":-65.542577,"median":-59.934431,"eighty":-58.653787,"marketCap":127231897878},{"date":"2021-01-22","current":-75.111578,"twenty":-69.798545,"median":-61.62536,"eighty":-58.836696,"marketCap":144977859301},{"date":"2021-01-29","current":-66.268267,"twenty":-70.935369,"median":-65.600453,"eighty":-58.920414,"marketCap":128966248334},{"date":"2021-02-05","current":-70.843724,"twenty":-71.160691,"median":-66.402516,"eighty":-59.472589,"marketCap":137044833867},{"date":"2021-02-11","current":-73.259421,"twenty":-72.388775,"median":-68.623378,"eighty":-59.909845,"marketCap":141921097207},{"date":"2021-02-19","current":-69.584878,"twenty":-72.910639,"median":-69.283721,"eighty":-60.353226,"marketCap":134861432372},{"date":"2021-02-26","current":-60.141164,"twenty":-72.481128,"median":-68.087003,"eighty":-60.420269,"marketCap":116302519660},{"date":"2021-03-05","current":-56.85889,"twenty":-72.0166,"median":-66.268267,"eighty":-60.074121,"marketCap":109679535123},{"date":"2021-03-12","current":-59.415349,"twenty":-71.520469,"median":-65.634307,"eighty":-59.099919,"marketCap":114410238364},{"date":"2021-03-19","current":-58.603337,"twenty":-71.014965,"median":-65.279781,"eighty":-58.980041,"marketCap":112809077267},{"date":"2021-03-26","current":-57.420101,"twenty":-70.801528,"median":-63.675052,"eighty":-58.456619,"marketCap":110043435373},{"date":"2021-04-01","current":-99.513447,"twenty":-72.111714,"median":-65.255751,"eighty":-58.603337,"marketCap":117685340607},{"date":"2021-04-09","current":-93.829103,"twenty":-73.100725,"median":-65.311073,"eighty":-58.727146,"marketCap":111207916170},{"date":"2021-04-16","current":-91.762285,"twenty":-74.85113,"median":-65.783649,"eighty":-58.836696,"marketCap":109170074775},{"date":"2021-04-23","current":-109.839824,"twenty":-90.431092,"median":-66.402516,"eighty":-58.920414,"marketCap":131004089730},{"date":"2021-04-30","current":-102.619464,"twenty":-91.452277,"median":-68.724058,"eighty":-59.011683,"marketCap":122897013046},{"date":"2021-05-07","current":-97.428671,"twenty":-96.409896,"median":-69.352117,"eighty":-59.213107,"marketCap":117436541495},{"date":"2021-05-14","current":-101.964808,"twenty":-97.632955,"median":-70.026533,"eighty":-59.379727,"marketCap":122824206759},{"date":"2021-05-21","current":-109.973218,"twenty":-99.103595,"median":-70.738235,"eighty":-59.57381,"marketCap":132507442977},{"date":"2021-05-28","current":-107.105119,"twenty":-100.222008,"median":-71.636143,"eighty":-59.909845,"marketCap":130323254356},{"date":"2021-06-04","current":-106.183195,"twenty":-103.047548,"median":-72.784205,"eighty":-60.090882,"marketCap":128588964422},{"date":"2021-06-11","current":-108.23655,"twenty":-104.283306,"median":-74.011578,"eighty":-60.308104,"marketCap":131066032292},{"date":"2021-06-18","current":-104.996815,"twenty":-104.950024,"median":-74.677498,"eighty":-60.754148,"marketCap":126111896552},{"date":"2021-06-25","current":-108.401163,"twenty":-105.285659,"median":-75.279371,"eighty":-61.553193,"marketCap":130118918107},{"date":"2021-07-02","current":-106.622678,"twenty":-106.183195,"median":-90.445668,"eighty":-61.619211,"marketCap":127760482537},{"date":"2021-07-09","current":-100.272231,"twenty":-106.183195,"median":-90.948745,"eighty":-61.62536,"marketCap":120030681653},{"date":"2021-07-16","current":-106.975494,"twenty":-106.622678,"median":-92.795694,"eighty":-61.712678,"marketCap":128052173136},{"date":"2021-07-23","current":-102.477274,"twenty":-106.622678,"median":-96.369361,"eighty":-62.277177,"marketCap":122655897047},{"date":"2021-07-30","current":-96.244101,"twenty":-106.531079,"median":-96.160202,"eighty":-62.43474,"marketCap":115582400012},{"date":"2021-08-06","current":-90.456671,"twenty":-106.183195,"median":-96.076303,"eighty":-63.026939,"marketCap":108369781827},{"date":"2021-08-13","current":-89.117798,"twenty":-106.148472,"median":-94.251891,"eighty":-64.323165,"marketCap":106911238330},{"date":"2021-08-20","current":-76.56893,"twenty":-106.141613,"median":-92.830432,"eighty":-65.231721,"marketCap":91596531611},{"date":"2021-08-27","current":-52.912902,"twenty":-105.631697,"median":-91.452399,"eighty":-63.026939,"marketCap":88752371792},{"date":"2021-09-03","current":-57.411891,"twenty":-105.383527,"median":-90.623704,"eighty":-61.62536,"marketCap":96337788726},{"date":"2021-09-10","current":-55.660683,"twenty":-105.292659,"median":-90.464692,"eighty":-60.141164,"marketCap":93639455507},{"date":"2021-09-17","current":-57.825782,"twenty":-105.258722,"median":-90.168186,"eighty":-59.326295,"marketCap":96994140050},{"date":"2021-09-24","current":-63.057451,"twenty":-105.257871,"median":-87.790274,"eighty":-59.397538,"marketCap":105818418957},{"date":"2021-09-30","current":-65.454027,"twenty":-105.205276,"median":-86.731586,"eighty":-59.427942,"marketCap":110207765023},{"date":"2021-10-08","current":-65.977203,"twenty":-105.066231,"median":-82.434007,"eighty":-59.619544,"marketCap":111083588321},{"date":"2021-10-15","current":-66.495128,"twenty":-104.917441,"median":-78.481513,"eighty":-59.76961,"marketCap":112032396894},{"date":"2021-10-22","current":-65.935102,"twenty":-104.784173,"median":-75.402004,"eighty":-59.909845,"marketCap":111886426345},{"date":"2021-10-29","current":-60.1915,"twenty":-104.573848,"median":-74.894538,"eighty":-59.969027,"marketCap":101887443690},{"date":"2021-11-05","current":-59.419571,"twenty":-104.241823,"median":-74.011578,"eighty":-59.426278,"marketCap":100746520293},{"date":"2021-11-12","current":-64.535702,"twenty":-104.144247,"median":-72.784205,"eighty":-59.558476,"marketCap":109872110899},{"date":"2021-11-19","current":-68.964255,"twenty":-103.89668,"median":-71.636143,"eighty":-59.76961,"marketCap":117245588109},{"date":"2021-11-26","current":-63.104,"twenty":-103.574286,"median":-70.738235,"eighty":-59.868596,"marketCap":107316945529},{"date":"2021-12-03","current":-56.970022,"twenty":-103.502791,"median":-69.584878,"eighty":-59.426278,"marketCap":97064410689},{"date":"2021-12-10","current":-56.787261,"twenty":-103.406584,"median":-69.317919,"eighty":-59.328306,"marketCap":96918229348},{"date":"2021-12-17","current":-46.241205,"twenty":-103.373136,"median":-68.872296,"eighty":-58.827693,"marketCap":78864833685},{"date":"2021-12-24","current":-42.300946,"twenty":-103.099197,"median":-68.604599,"eighty":-58.435519,"marketCap":72213582651},{"date":"2021-12-31","current":-41.234857,"twenty":-102.722762,"median":-67.767406,"eighty":-58.065904,"marketCap":70546743038},{"date":"2022-01-07","current":-34.486195,"twenty":-40.275969,"median":-37.64864,"eighty":-34.378339,"marketCap":58776768292},{"date":"2022-01-14","current":-37.878055,"twenty":-39.829817,"median":-37.763347,"eighty":-34.687526,"marketCap":64698308382},{"date":"2022-01-21","current":-35.699125,"twenty":-39.504145,"median":-36.722111,"eighty":-34.943651,"marketCap":61116142155},{"date":"2022-01-28","current":-26.329119,"twenty":-38.684591,"median":-35.628932,"eighty":-34.378339,"marketCap":44959841418},{"date":"2022-02-04","current":-26.846632,"twenty":-38.167145,"median":-35.414472,"eighty":-33.988231,"marketCap":45821080875},{"date":"2022-02-11","current":-27.092592,"twenty":-37.878055,"median":-35.02492,"eighty":-28.311865,"marketCap":46334276980},{"date":"2022-02-18","current":-29.050449,"twenty":-37.64864,"median":-34.653971,"eighty":-28.311865,"marketCap":49926649721},{"date":"2022-02-25","current":-29.744971,"twenty":-36.735769,"median":-33.988231,"eighty":-27.979692,"marketCap":51246296850},{"date":"2022-03-04","current":-27.223879,"twenty":-36.722111,"median":-29.802166,"eighty":-27.979692,"marketCap":46920786816},{"date":"2022-03-11","current":-23.132687,"twenty":-36.621639,"median":-29.36929,"eighty":-27.223879,"marketCap":39809355064},{"date":"2022-03-18","current":-23.353608,"twenty":-35.699125,"median":-29.07698,"eighty":-26.329119,"marketCap":40029296252},{"date":"2022-03-25","current":-23.609253,"twenty":-35.558739,"median":-28.622989,"eighty":-24.861144,"marketCap":40469178628},{"date":"2022-04-01","current":-10.302966,"twenty":-35.270205,"median":-28.485417,"eighty":-23.573298,"marketCap":39809355064},{"date":"2022-04-08","current":-10.829548,"twenty":-35.143591,"median":-28.187716,"eighty":-23.264469,"marketCap":41862139487},{"date":"2022-04-14","current":-10.543533,"twenty":-35.059727,"median":-27.88961,"eighty":-22.413734,"marketCap":40689119817},{"date":"2022-04-22","current":-10.163583,"twenty":-34.960508,"median":-27.608169,"eighty":-14.664685,"marketCap":38489707935},{"date":"2022-04-29","current":-9.896969,"twenty":-34.847033,"median":-27.171587,"eighty":-10.835566,"marketCap":36876805888},{"date":"2022-05-06","current":-7.794072,"twenty":-34.754637,"median":-27.092592,"eighty":-10.351079,"marketCap":28800028988},{"date":"2022-05-13","current":-7.531991,"twenty":-34.486195,"median":-26.329119,"eighty":-10.163583,"marketCap":27333632400},{"date":"2022-05-20","current":-9.06555,"twenty":-34.216555,"median":-24.981857,"eighty":-9.94212,"marketCap":33360522377},{"date":"2022-05-27","current":-8.694531,"twenty":-33.988231,"median":-24.386135,"eighty":-9.493302,"marketCap":31967445618},{"date":"2022-06-02","current":-9.642455,"twenty":-32.008842,"median":-23.573298,"eighty":-9.445349,"marketCap":35642983659},{"date":"2022-06-10","current":-10.68648,"twenty":-30.190287,"median":-23.325512,"eighty":-9.612624,"marketCap":39236617814},{"date":"2022-06-17","current":-10.7582,"twenty":-29.767849,"median":-23.119688,"eighty":-9.67054,"marketCap":39456636231},{"date":"2022-06-24","current":-14.400248,"twenty":-29.698416,"median":-20.893648,"eighty":-9.677673,"marketCap":53024438653},{"date":"2022-06-30","current":-13.932533,"twenty":-29.496285,"median":-17.024829,"eighty":-9.74948,"marketCap":51213898589},{"date":"2022-07-08","current":-14.67593,"twenty":-29.3239,"median":-15.17553,"eighty":-9.857114,"marketCap":54002047796},{"date":"2022-07-15","current":-14.83334,"twenty":-29.179562,"median":-14.952896,"eighty":-9.904546,"marketCap":54075420144},{"date":"2022-07-22","current":-14.019077,"twenty":-29.071673,"median":-14.83334,"eighty":-9.929111,"marketCap":51140526242},{"date":"2022-07-29","current":-13.158261,"twenty":-28.820464,"median":-14.63277,"eighty":-9.965579,"marketCap":48058887645},{"date":"2022-08-05","current":-14.452099,"twenty":-28.640649,"median":-14.521363,"eighty":-10.047766,"marketCap":52650020045},{"date":"2022-08-12","current":-14.71463,"twenty":-28.603223,"median":-14.534456,"eighty":-10.093451,"marketCap":53679489711},{"date":"2022-08-19","current":-14.001057,"twenty":-28.570837,"median":-14.521363,"eighty":-10.095676,"marketCap":50565103155},{"date":"2022-08-26","current":-15.136454,"twenty":-28.470894,"median":-14.486731,"eighty":-10.136779,"marketCap":53314867072},{"date":"2022-09-02","current":-13.75829,"twenty":-28.35224,"median":-14.400248,"eighty":-10.174316,"marketCap":48286589223},{"date":"2022-09-09","current":-12.67453,"twenty":-28.162886,"median":-14.340141,"eighty":-10.188715,"marketCap":44313642009},{"date":"2022-09-16","current":-11.97665,"twenty":-28.030016,"median":-14.29062,"eighty":-10.196162,"marketCap":41486737260},{"date":"2022-09-23","current":-10.816798,"twenty":-27.907626,"median":-14.221409,"eighty":-10.24124,"marketCap":36749761735},{"date":"2022-09-30","current":-10.989799,"twenty":-27.744526,"median":-14.086255,"eighty":-10.312544,"marketCap":37408857483},{"date":"2022-10-07","current":-10.967956,"twenty":-27.640481,"median":-14.000529,"eighty":-10.336741,"marketCap":37332356752},{"date":"2022-10-14","current":-11.448997,"twenty":-27.488229,"median":-13.89571,"eighty":-10.263806,"marketCap":38556368449},{"date":"2022-10-21","current":-13.815232,"twenty":-27.213421,"median":-13.759398,"eighty":-10.307755,"marketCap":46206441554},{"date":"2022-10-28","current":-12.395469,"twenty":-27.165938,"median":-13.60575,"eighty":-10.336584,"marketCap":41386895498},{"date":"2022-11-04","current":-14.340639,"twenty":-27.133191,"median":-13.618391,"eighty":-10.375435,"marketCap":48347495967},{"date":"2022-11-11","current":-14.799648,"twenty":-27.0434,"median":-13.75829,"eighty":-10.403849,"marketCap":50339627338},{"date":"2022-11-18","current":-14.669694,"twenty":-26.743129,"median":-13.855471,"eighty":-10.5207,"marketCap":49726663840},{"date":"2022-11-25","current":-12.759206,"twenty":-26.31944,"median":-13.760506,"eighty":-10.550481,"marketCap":42907444916},{"date":"2022-12-02","current":-12.446274,"twenty":-26.045094,"median":-13.719165,"eighty":-10.589876,"marketCap":42577469882},{"date":"2022-12-09","current":-14.33147,"twenty":-25.054285,"median":-13.649228,"eighty":-10.646322,"marketCap":49481924457},{"date":"2022-12-16","current":-14.387249,"twenty":-24.801403,"median":-13.759398,"eighty":-10.697091,"marketCap":49558640619},{"date":"2022-12-23","current":-14.560885,"twenty":-24.527177,"median":-13.788181,"eighty":-10.74327,"marketCap":50172369915},{"date":"2022-12-30","current":-14.738058,"twenty":-24.421396,"median":-13.826106,"eighty":-10.754467,"marketCap":51399828506},{"date":"2023-01-06","current":-14.850279,"twenty":-23.920006,"median":-13.912069,"eighty":-10.764544,"marketCap":52323278120},{"date":"2023-01-13","current":-18.011522,"twenty":-23.58768,"median":-13.988706,"eighty":-10.797588,"marketCap":64675254333},{"date":"2023-01-20","current":-18.576885,"twenty":-23.451175,"median":-14.010067,"eighty":-10.824448,"marketCap":66132940967},{"date":"2023-01-27","current":-20.253712,"twenty":-23.369759,"median":-14.086255,"eighty":-10.829548,"marketCap":72117128201},{"date":"2023-02-03","current":-19.550889,"twenty":-23.353608,"median":-14.221409,"eighty":-10.844594,"marketCap":69975086836},{"date":"2023-02-10","current":-18.461328,"twenty":-23.297415,"median":-14.245235,"eighty":-10.967956,"marketCap":65678370978},{"date":"2023-02-17","current":-17.287694,"twenty":-23.132687,"median":-14.283163,"eighty":-10.989799,"marketCap":60921292706},{"date":"2023-02-24","current":-16.928562,"twenty":-23.119688,"median":-14.316312,"eighty":-11.024034,"marketCap":58926388915},{"date":"2023-03-03","current":-18.506493,"twenty":-22.859931,"median":-14.340639,"eighty":-11.034338,"marketCap":64834373220},{"date":"2023-03-10","current":-17.143751,"twenty":-18.007033,"median":-17.594016,"eighty":-17.406062,"marketCap":59616932535},{"date":"2023-03-17","current":-18.225066,"twenty":-64.535702,"median":-27.223879,"eighty":-8.33302,"marketCap":63990375462},{"date":"2023-03-24","current":-16.635504,"twenty":-64.428087,"median":-27.157464,"eighty":-8.3397,"marketCap":59079843053},{"date":"2023-03-31","current":-21.665543,"twenty":-64.392731,"median":-27.092592,"eighty":-8.34275,"marketCap":53939129436},{"date":"2023-04-06","current":-23.653196,"twenty":-64.390621,"median":-26.634155,"eighty":-8.352405,"marketCap":58849661846},{"date":"2023-04-14","current":-26.320033,"twenty":-64.362795,"median":-26.324576,"eighty":-8.358879,"marketCap":65549469340},{"date":"2023-04-21","current":-23.835896,"twenty":-64.30121,"median":-26.271674,"eighty":-8.365503,"marketCap":59332248009},{"date":"2023-04-28","current":-23.269102,"twenty":-64.264448,"median":-25.584933,"eighty":-8.381733,"marketCap":57490108356},{"date":"2023-05-05","current":-25.40213,"twenty":-64.226366,"median":-25.443671,"eighty":-8.392457,"marketCap":62863015679},{"date":"2023-05-12","current":-24.841882,"twenty":-63.995645,"median":-25.285405,"eighty":-8.397793,"marketCap":61053226682},{"date":"2023-05-19","current":-24.150302,"twenty":-63.567828,"median":-25.133368,"eighty":-8.401129,"marketCap":58518941801},{"date":"2023-05-25","current":-24.040915,"twenty":-63.478503,"median":-25.133368,"eighty":-8.403051,"marketCap":57981366220},{"date":"2023-06-02","current":-23.630086,"twenty":-63.473336,"median":-25.04176,"eighty":-8.412356,"marketCap":56829418547},{"date":"2023-06-09","current":-24.154309,"twenty":-63.449017,"median":-24.911552,"eighty":-8.424162,"marketCap":58006344624},{"date":"2023-06-16","current":-23.65814,"twenty":-63.399642,"median":-24.844401,"eighty":-8.424971,"marketCap":56542705118},{"date":"2023-06-23","current":-19.736815,"twenty":-63.261636,"median":-24.800239,"eighty":-8.430589,"marketCap":46913497843},{"date":"2023-06-30","current":-19.361003,"twenty":-63.08538,"median":-24.583422,"eighty":-8.44223,"marketCap":45603925654},{"date":"2023-07-07","current":-19.824835,"twenty":-63.045246,"median":-24.39464,"eighty":-8.448328,"marketCap":46605363211},{"date":"2023-07-14","current":-20.972988,"twenty":-63.025798,"median":-24.281068,"eighty":-8.448858,"marketCap":49996366985},{"date":"2023-07-21","current":-21.298184,"twenty":-63.023861,"median":-24.205923,"eighty":-8.451759,"marketCap":50535619017},{"date":"2023-07-28","current":-23.791121,"twenty":-62.900857,"median":-24.161547,"eighty":-8.45846,"marketCap":56390355367},{"date":"2023-08-04","current":-21.285622,"twenty":-62.621827,"median":-24.152023,"eighty":-8.468652,"marketCap":50535619017},{"date":"2023-08-11","current":-21.635252,"twenty":-62.473049,"median":-24.087847,"eighty":-8.483716,"marketCap":51075672185},{"date":"2023-08-18","current":-20.673771,"twenty":-62.457914,"median":-23.929713,"eighty":-8.495975,"marketCap":48456406945},{"date":"2023-08-25","current":-35.378703,"twenty":-62.412077,"median":-24.023529,"eighty":-8.502433,"marketCap":52077155954},{"date":"2023-09-01","current":-36.587783,"twenty":-62.312576,"median":-24.142541,"eighty":-8.513294,"marketCap":54080524613},{"date":"2023-09-08","current":-37.287346,"twenty":-62.243984,"median":-24.154309,"eighty":-8.541071,"marketCap":54465713535},{"date":"2023-09-15","current":-41.061694,"twenty":-62.09617,"median":-24.166632,"eighty":-8.556024,"marketCap":60443963680},{"date":"2023-09-22","current":-41.150073,"twenty":-62.027557,"median":-24.212626,"eighty":-8.57503,"marketCap":60309214704},{"date":"2023-09-29","current":-41.957156,"twenty":-61.990984,"median":-24.362375,"eighty":-8.585232,"marketCap":61597529037},{"date":"2023-10-06","current":-42.818398,"twenty":-61.979722,"median":-24.399805,"eighty":-8.60704,"marketCap":62831819583},{"date":"2023-10-13","current":-48.929979,"twenty":-61.964165,"median":-24.604406,"eighty":-8.63324,"marketCap":71692717216},{"date":"2023-10-20","current":-48.564987,"twenty":-61.809044,"median":-24.821061,"eighty":-8.647132,"marketCap":71048288297},{"date":"2023-10-27","current":-49.577379,"twenty":-61.731951,"median":-24.852773,"eighty":-8.67951,"marketCap":72498253365},{"date":"2023-11-03","current":-50.935903,"twenty":-61.695214,"median":-24.911552,"eighty":-8.688438,"marketCap":74682635412},{"date":"2023-11-10","current":-51.497919,"twenty":-61.695214,"median":-24.911552,"eighty":-8.688438,"marketCap":75490889042},{"date":"2023-11-17","current":-48.797205,"twenty":-61.564351,"median":-24.911552,"eighty":-8.688438,"marketCap":72177049159},{"date":"2023-11-24","current":-47.423194,"twenty":-61.037754,"median":-24.911552,"eighty":-8.688438,"marketCap":70722192625},{"date":"2023-12-01","current":-47.541194,"twenty":-60.124403,"median":-24.911552,"eighty":-8.688438,"marketCap":71192149820},{"date":"2023-12-08","current":-43.123442,"twenty":-59.680613,"median":-24.911552,"eighty":-8.688438,"marketCap":64315635348},{"date":"2023-12-15","current":-45.518514,"twenty":-59.330317,"median":-24.911552,"eighty":-8.688438,"marketCap":68279743691},{"date":"2023-12-22","current":-41.339438,"twenty":-58.771185,"median":-24.911552,"eighty":-8.688438,"marketCap":61969530411},{"date":"2023-12-29","current":-45.897864,"twenty":-58.451098,"median":-24.911552,"eighty":-8.688438,"marketCap":69169645563},{"date":"2024-01-05","current":-41.6186,"twenty":-58.024001,"median":-24.911552,"eighty":-8.688438,"marketCap":62278306752},{"date":"2024-01-12","current":-43.437966,"twenty":-57.418459,"median":-24.911552,"eighty":-8.688438,"marketCap":65035419290},{"date":"2024-01-19","current":-39.267262,"twenty":-56.725823,"median":-24.911552,"eighty":-8.688438,"marketCap":58710278761},{"date":"2024-01-26","current":-36.31712,"twenty":-55.836725,"median":-24.911552,"eighty":-8.688438,"marketCap":54088060681},{"date":"2024-02-02","current":-34.853132,"twenty":-55.005219,"median":-24.911552,"eighty":-8.688438,"marketCap":51841523559},{"date":"2024-02-09","current":-39.078682,"twenty":-54.567045,"median":-24.977375,"eighty":-8.690942,"marketCap":58412984292},{"date":"2024-02-16","current":-43.519901,"twenty":-53.86795,"median":-24.961961,"eighty":-8.689273,"marketCap":65065574169},{"date":"2024-02-23","current":-43.423228,"twenty":-53.453001,"median":-24.961961,"eighty":-8.689273,"marketCap":64578799300},{"date":"2024-03-01","current":-43.287126,"twenty":-53.199825,"median":-24.969668,"eighty":-8.690107,"marketCap":64416541010},{"date":"2024-03-08","current":-42.88643,"twenty":-52.44341,"median":-24.969668,"eighty":-8.690107,"marketCap":63848636996},{"date":"2024-03-15","current":-46.524187,"twenty":-51.488905,"median":-25.009567,"eighty":-8.693429,"marketCap":69203160557},{"date":"2024-03-22","current":-52.308694,"twenty":-51.849485,"median":-25.232473,"eighty":-8.716682,"marketCap":58412984292},{"date":"2024-03-28","current":-54.97427,"twenty":-52.93553,"median":-25.488194,"eighty":-8.784794,"marketCap":61171375216},{"date":"2024-04-05","current":-52.146452,"twenty":-52.985136,"median":-25.87886,"eighty":-8.870004,"marketCap":58007338567},{"date":"2024-04-12","current":-54.452719,"twenty":-53.302804,"median":-26.375398,"eighty":-8.942783,"marketCap":60607206202},{"date":"2024-04-19","current":-48.443774,"twenty":-53.302804,"median":-27.157464,"eighty":-9.068996,"marketCap":53873072180},{"date":"2024-04-26","current":-57.196236,"twenty":-53.435518,"median":-27.450523,"eighty":-9.167423,"marketCap":63528035417},{"date":"2024-05-03","current":-59.794233,"twenty":-53.777852,"median":-27.730775,"eighty":-9.397396,"marketCap":66367730487},{"date":"2024-05-10","current":-60.546292,"twenty":-54.435313,"median":-28.113255,"eighty":-9.857114,"marketCap":67362014561},{"date":"2024-05-17","current":-58.658055,"twenty":-54.574873,"median":-28.485417,"eighty":-9.977493,"marketCap":65165427130},{"date":"2024-05-24","current":-52.700238,"twenty":-54.976338,"median":-29.07698,"eighty":-10.139927,"marketCap":58412954655},{"date":"2024-05-31","current":-51.620118,"twenty":-54.976338,"median":-29.361089,"eighty":-10.283386,"marketCap":57273983395},{"date":"2024-06-07","current":-52.565196,"twenty":-54.976338,"median":-30.241673,"eighty":-10.532117,"marketCap":58250244475},{"date":"2024-06-14","current":-56.319381,"twenty":-54.981036,"median":-31.054417,"eighty":-10.718314,"marketCap":62353269027},{"date":"2024-06-21","current":-54.227183,"twenty":-55.099632,"median":-32.881149,"eighty":-10.838576,"marketCap":59911234992},{"date":"2024-06-28","current":-54.249689,"twenty":-55.440028,"median":-33.56094,"eighty":-11.097775,"marketCap":59911234992},{"date":"2024-07-05","current":-58.463788,"twenty":-55.657871,"median":-34.005125,"eighty":-11.220642,"marketCap":64551099658},{"date":"2024-07-12","current":-59.938373,"twenty":-55.745963,"median":-34.181189,"eighty":-11.407271,"marketCap":66276432299},{"date":"2024-07-19","current":-59.716353,"twenty":-55.97848,"median":-34.545269,"eighty":-11.738708,"marketCap":66032170263},{"date":"2024-07-26","current":-57.074426,"twenty":-56.131334,"median":-34.806278,"eighty":-12.250774,"marketCap":63345287873},{"date":"2024-08-02","current":-57.621526,"twenty":-56.307104,"median":-34.994572,"eighty":-12.425719,"marketCap":63915232622},{"date":"2024-08-09","current":-60.772336,"twenty":-56.714024,"median":-35.324454,"eighty":-12.694151,"marketCap":67859465726},{"date":"2024-08-16","current":-59.654815,"twenty":-57.048523,"median":-35.648167,"eighty":-12.850581,"marketCap":66637506560},{"date":"2024-08-23","current":-63.107395,"twenty":-57.458873,"median":-35.962733,"eighty":-13.047453,"marketCap":70792167727},{"date":"2024-08-30","current":-49.12916,"twenty":-57.66299,"median":-36.345755,"eighty":-13.206187,"marketCap":69162888838},{"date":"2024-09-06","current":-49.915263,"twenty":-57.66299,"median":-36.567164,"eighty":-13.37092,"marketCap":70303384060},{"date":"2024-09-13","current":-51.145513,"twenty":-57.66299,"median":-36.671875,"eighty":-13.573848,"marketCap":71847570529},{"date":"2024-09-20","current":-49.167101,"twenty":-57.683721,"median":-36.986342,"eighty":-13.63831,"marketCap":69482554019},{"date":"2024-09-27","current":-53.462204,"twenty":-57.683721,"median":-37.445773,"eighty":-13.783867,"marketCap":76006737495},{"date":"2024-10-04","current":-58.949991,"twenty":-57.776104,"median":-37.558101,"eighty":-13.908798,"marketCap":83427996199},{"date":"2024-10-10","current":-56.643507,"twenty":-57.816343,"median":-37.60917,"eighty":-13.995484,"marketCap":79676590700},{"date":"2024-10-18","current":-54.316933,"twenty":-57.819489,"median":-37.924768,"eighty":-14.224435,"marketCap":75975160467},{"date":"2024-10-25","current":-51.747614,"twenty":-57.819489,"median":-38.255535,"eighty":-14.2894,"marketCap":72376767507},{"date":"2024-11-01","current":-40.961176,"twenty":-57.819489,"median":-38.986697,"eighty":-14.340877,"marketCap":57328942398},{"date":"2024-11-08","current":-45.608937,"twenty":-57.819489,"median":-39.308677,"eighty":-14.420988,"marketCap":63544348421},{"date":"2024-11-15","current":-44.200719,"twenty":-57.819489,"median":-39.497388,"eighty":-14.54548,"marketCap":60930246271},{"date":"2024-11-22","current":-43.988394,"twenty":-57.819489,"median":-39.586206,"eighty":-14.672188,"marketCap":60602664302},{"date":"2024-11-29","current":-45.857239,"twenty":-57.819489,"median":-39.778153,"eighty":-14.785857,"marketCap":63141424563},{"date":"2024-12-06","current":-45.071237,"twenty":-57.819489,"median":-40.220709,"eighty":-14.848685,"marketCap":61912992178},{"date":"2024-12-13","current":-44.682481,"twenty":-57.819489,"median":-40.576246,"eighty":-15.014493,"marketCap":61257828240},{"date":"2024-12-20","current":-42.241276,"twenty":-57.819489,"median":-40.934902,"eighty":-15.254477,"marketCap":57654426579},{"date":"2024-12-27","current":-42.754459,"twenty":-57.819489,"median":-40.969369,"eighty":-15.339213,"marketCap":58309590517},{"date":"2025-01-03","current":-42.534452,"twenty":-57.819489,"median":-41.085429,"eighty":-15.481309,"marketCap":58066335414},{"date":"2025-01-10","current":-40.407856,"twenty":-57.819489,"median":-41.176668,"eighty":-16.193782,"marketCap":54954176393},{"date":"2025-01-17","current":-37.851954,"twenty":-57.819489,"median":-41.179186,"eighty":-16.682563,"marketCap":51519723275},{"date":"2025-01-24","current":-38.69271,"twenty":-57.819489,"median":-41.179186,"eighty":-16.915608,"marketCap":52994055579},{"date":"2025-01-28","current":-39.34211,"twenty":-57.816343,"median":-41.177927,"eighty":-16.989137,"marketCap":54140758482},{"date":"2025-02-07","current":-43.376749,"twenty":-57.822636,"median":-41.225174,"eighty":-17.320246,"marketCap":59382828895},{"date":"2025-02-14","current":-44.895241,"twenty":-57.822636,"median":-41.439791,"eighty":-17.61594,"marketCap":61432031400},{"date":"2025-02-21","current":-49.746076,"twenty":-57.822636,"median":-41.616926,"eighty":-17.999791,"marketCap":68312418916},{"date":"2025-02-28","current":-48.414447,"twenty":-57.822636,"median":-41.739825,"eighty":-18.237812,"marketCap":66264684536},{"date":"2025-03-07","current":-47.922812,"twenty":-57.825782,"median":-42.027254,"eighty":-18.551688,"marketCap":65855137660},{"date":"2025-03-14","current":-48.79914,"twenty":-57.825782,"median":-42.125115,"eighty":-18.662738,"marketCap":67083778288},{"date":"2025-03-21","current":-48.401057,"twenty":-57.825782,"median":-42.299167,"eighty":-18.935846,"marketCap":66510412662},{"date":"2025-03-28","current":-55.188745,"twenty":-57.825782,"median":-42.496478,"eighty":-19.437399,"marketCap":75684262684},{"date":"2025-04-03","current":-812.530138,"twenty":-57.971959,"median":-42.563523,"eighty":-19.437399,"marketCap":82318922076},{"date":"2025-04-11","current":-779.078321,"twenty":-58.17521,"median":-42.754459,"eighty":-19.437399,"marketCap":78223453316},{"date":"2025-04-17","current":-769.900239,"twenty":-58.259802,"median":-42.852414,"eighty":-19.446154,"marketCap":77404359564},{"date":"2025-04-25","current":-889.264014,"twenty":-58.573908,"median":-42.97387,"eighty":-19.435927,"marketCap":89578154558},{"date":"2025-05-02","current":-896.357794,"twenty":-58.735668,"median":-42.988967,"eighty":-19.437399,"marketCap":90484649223},{"date":"2025-05-09","current":-849.575932,"twenty":-58.959846,"median":-43.1845,"eighty":-19.435927,"marketCap":86364218930},{"date":"2025-05-16","current":-820.85164,"twenty":-59.318718,"median":-43.369817,"eighty":-19.435927,"marketCap":84125961099},{"date":"2025-05-23","current":-940.361806,"twenty":-59.416193,"median":-43.416299,"eighty":-19.435927,"marketCap":96662378831},{"date":"2025-05-30","current":-989.768217,"twenty":-59.721419,"median":-43.519443,"eighty":-19.435927,"marketCap":102188299805},{"date":"2025-06-06","current":-1165.735261,"twenty":-59.85563,"median":-43.586357,"eighty":-19.435927,"marketCap":120663020674},{"date":"2025-06-13","current":-1287.14885,"twenty":-60.074121,"median":-43.654071,"eighty":-19.435927,"marketCap":133282988343},{"date":"2025-06-20","current":-1241.733329,"twenty":-60.490073,"median":-43.829003,"eighty":-19.435927,"marketCap":128328230412},{"date":"2025-06-27","current":-1232.687947,"twenty":-60.772336,"median":-43.882417,"eighty":-19.437399,"marketCap":127750175320},{"date":"2025-06-30","current":-1248.706528,"twenty":-60.856179,"median":-43.894007,"eighty":-19.437399,"marketCap":129484340596}],"updateTime":1751406063734}}}